Jaime Masjuan Vallejo , Ángel Cequier Fillat , Víctor Expósito García , Carmen Suárez Fernández , Inmaculada Roldán Rabadán , Román Freixa-Pamias , Alejandro Isidoro Pérez Cabeza , Alfonso Valle Muñoz , Ignacio Fernández Lozano
{"title":"房颤患者中风的预防。在COVID-19时代加强保护","authors":"Jaime Masjuan Vallejo , Ángel Cequier Fillat , Víctor Expósito García , Carmen Suárez Fernández , Inmaculada Roldán Rabadán , Román Freixa-Pamias , Alejandro Isidoro Pérez Cabeza , Alfonso Valle Muñoz , Ignacio Fernández Lozano","doi":"10.1016/S1131-3587(21)00002-9","DOIUrl":null,"url":null,"abstract":"<div><p>Atrial fibrillation is associated with up to a five-fold increase in the risk of stroke. Cardioembolic stroke is usually more severe than other types of stroke and has higher rates of recurrence and permanent disability. Consequently, reducing the risk of stroke through adequate anticoagulation is one of the main goals of treatment in patients with atrial fibrillation. Vitamin K antagonists have been largely superseded by direct oral anticoagulants because the results of clinical trials, real-life studies and, recently, population studies have all demonstrated that direct oral anticoagulants are more effective (i.e. the risk of stroke and death is lower) and safer (i.e. the risk of intracranial hemorrhage is lower) than vitamin K antagonists. In addition, COVID-19 pandemic, the preferential use of direct oral anticoagulants instead of vitamin K antagonists has been a key strategy for ensuring that the quality of anticoagulation is optimal and that patients are better protected against SARS-CoV-2 infection, as no international normalized ratio control is required.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1131-3587(21)00002-9","citationCount":"1","resultStr":"{\"title\":\"Prevención del ictus en pacientes con fibrilación auricular. Mejorar la protección enla era de la COVID-19\",\"authors\":\"Jaime Masjuan Vallejo , Ángel Cequier Fillat , Víctor Expósito García , Carmen Suárez Fernández , Inmaculada Roldán Rabadán , Román Freixa-Pamias , Alejandro Isidoro Pérez Cabeza , Alfonso Valle Muñoz , Ignacio Fernández Lozano\",\"doi\":\"10.1016/S1131-3587(21)00002-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Atrial fibrillation is associated with up to a five-fold increase in the risk of stroke. Cardioembolic stroke is usually more severe than other types of stroke and has higher rates of recurrence and permanent disability. Consequently, reducing the risk of stroke through adequate anticoagulation is one of the main goals of treatment in patients with atrial fibrillation. Vitamin K antagonists have been largely superseded by direct oral anticoagulants because the results of clinical trials, real-life studies and, recently, population studies have all demonstrated that direct oral anticoagulants are more effective (i.e. the risk of stroke and death is lower) and safer (i.e. the risk of intracranial hemorrhage is lower) than vitamin K antagonists. In addition, COVID-19 pandemic, the preferential use of direct oral anticoagulants instead of vitamin K antagonists has been a key strategy for ensuring that the quality of anticoagulation is optimal and that patients are better protected against SARS-CoV-2 infection, as no international normalized ratio control is required.</p></div>\",\"PeriodicalId\":34926,\"journal\":{\"name\":\"Revista Espanola de Cardiologia Suplementos\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S1131-3587(21)00002-9\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Espanola de Cardiologia Suplementos\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1131358721000029\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola de Cardiologia Suplementos","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1131358721000029","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Prevención del ictus en pacientes con fibrilación auricular. Mejorar la protección enla era de la COVID-19
Atrial fibrillation is associated with up to a five-fold increase in the risk of stroke. Cardioembolic stroke is usually more severe than other types of stroke and has higher rates of recurrence and permanent disability. Consequently, reducing the risk of stroke through adequate anticoagulation is one of the main goals of treatment in patients with atrial fibrillation. Vitamin K antagonists have been largely superseded by direct oral anticoagulants because the results of clinical trials, real-life studies and, recently, population studies have all demonstrated that direct oral anticoagulants are more effective (i.e. the risk of stroke and death is lower) and safer (i.e. the risk of intracranial hemorrhage is lower) than vitamin K antagonists. In addition, COVID-19 pandemic, the preferential use of direct oral anticoagulants instead of vitamin K antagonists has been a key strategy for ensuring that the quality of anticoagulation is optimal and that patients are better protected against SARS-CoV-2 infection, as no international normalized ratio control is required.
期刊介绍:
Revista Española de Cardiología, is an international scientific journal dealing with cardiovascular medicine. Revista Española de Cardiología, the official publication of the Spanish Society of Cardiology, publishes research articles related to cardiovascular diseases. Articles are published in Spanish for the paper edition and in both Spanish and English in the electronic edition, which is available on the Internet. Regular sections include original articles reporting clinical or basic research, brief reports, review articles, editorials and letters to the Editor.